Ally Bridge Group (NY) LLC — 13F holdings

Ally Bridge Group (NY) LLC reported 25 holdings worth $113M in its 13F filing for Q2 2026, filed August 14, 2026. That's down 8.7% from $124M in Q1 2026, when it reported 28 holdings. Its 10 largest positions make up 70.5% of the portfolio.

Ally Bridge Group (NY) LLC's largest positions in Q2 2026

  1. DFTX DEFINIUM THERAPEUTICS INC — $18.8M (16.6%) · new position
  2. ABVX ABIVAX SA — $16.7M (14.7%) · added 271%
  3. NERV MINERVA NEUROSCIENCES INC — $12.1M (10.7%) · added 31%
  4. PMN PROMIS NEUROSCIENCES INC — $8.16M (7.2%) · added 50%
  5. TRAX FIRST TRACKS BIOTHERAPEUTICS — $5.72M (5.1%) · new position
  6. AXSM AXSOME THERAPEUTICS INC — $4.04M (3.6%) · new position
  7. ASMB ASSEMBLY BIOSCIENCES INC — $3.85M (3.4%) · new position
  8. WHWK WHITEHAWK THERAPEUTICS INC — $3.75M (3.3%) · unchanged
  9. EWTX EDGEWISE THERAPEUTICS INC — $3.38M (3.0%) · cut 48%
  10. CLYM CLIMB BIO INC — $3.25M (2.9%) · new position
  11. KURA KURA ONCOLOGY INC — $3.18M (2.8%) · new position
  12. CTMX CYTOMX THERAPEUTICS INC — $2.91M (2.6%) · cut 14%
  13. AVTX AVALO THERAPEUTICS INC — $2.77M (2.5%) · new position
  14. PALI PALISADE BIO INC — $2.57M (2.3%) · new position
  15. SLDB SOLID BIOSCIENCES INC — $2.56M (2.3%) · cut 67%
  16. ANTX AN2 THERAPEUTICS INC — $2.55M (2.3%) · unchanged
  17. URGN UROGEN PHARMA LTD — $2.55M (2.3%) · cut 66%
  18. CATX PERSPECTIVE THERAPEUTICS INC — $2.54M (2.2%) · cut 20%
  19. IDYA IDEAYA BIOSCIENCES INC — $2.52M (2.2%) · new position
  20. IVA INVENTIVA SA — $2.40M (2.1%) · cut 15%

What Ally Bridge Group (NY) LLC bought in Q2 2026

11 new positions and 3 positions added to.

  1. DFTX DEFINIUM THERAPEUTICS INC — new position, about $18.8M
  2. ABVX ABIVAX SA — added, about $12.2M
  3. TRAX FIRST TRACKS BIOTHERAPEUTICS — new position, about $5.72M
  4. AXSM AXSOME THERAPEUTICS INC — new position, about $4.04M
  5. ASMB ASSEMBLY BIOSCIENCES INC — new position, about $3.85M
  6. CLYM CLIMB BIO INC — new position, about $3.25M
  7. KURA KURA ONCOLOGY INC — new position, about $3.18M
  8. NERV MINERVA NEUROSCIENCES INC — added, about $2.89M
  9. AVTX AVALO THERAPEUTICS INC — new position, about $2.77M
  10. PMN PROMIS NEUROSCIENCES INC — added, about $2.71M

What Ally Bridge Group (NY) LLC sold in Q2 2026

12 positions sold out and 9 reduced.

  1. CMPS COMPASS PATHWAYS PLC — sold out, about $14.8M
  2. QURE UNIQURE NV — sold out, about $13.8M
  3. SLNO SOLENO THERAPEUTICS INC — sold out, about $13.4M
  4. PRAX PRAXIS PRECISION MEDICINES I — sold out, about $11.0M
  5. OVID OVID THERAPEUTICS INC — cut 78%, about $5.90M
  6. SLDB SOLID BIOSCIENCES INC — cut 67%, about $5.11M
  7. TARS TARSUS PHARMACEUTICALS INC — sold out, about $5.09M
  8. URGN UROGEN PHARMA LTD — cut 66%, about $4.89M
  9. EWTX EDGEWISE THERAPEUTICS INC — cut 48%, about $3.16M
  10. EPRX EUPRAXIA PHARMACEUTICALS INC — cut 62%, about $2.70M

Ally Bridge Group (NY) LLC portfolio value by quarter

What does Ally Bridge Group (NY) LLC own?

Its largest positions in Q2 2026 were DFTX, ABVX, NERV, PMN, TRAX, out of 25 holdings worth $113M.

What did Ally Bridge Group (NY) LLC buy last quarter?

In Q2 2026 it opened 11 new positions and added to 3; the largest buys were DFTX, ABVX, TRAX.

What did Ally Bridge Group (NY) LLC sell last quarter?

In Q2 2026 it sold out of 12 positions and reduced 9, including CMPS, QURE, SLNO.